An interventional study of Traditional care habituation programme and Embrace Plus wristband in Psychological Disability and Mental Disability, sponsored by Pôle Saint Hélier. Not yet recruiting at 2 sites in France. Open to participants aged 9 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The RASSURE study aims to evaluate the effect of a preparation for care programme combining a traditional habituation method with a digital immersive virtual reality tool ('PREPASOINS_VR'), compared with traditional habituation alone. In particular, the study aims to measure the impact of the use of IVR on the anxiety experienced during the actual treatment, as well as on various indicators relating to the delivery of the treatment, its progress and the experience of the patients.
Pôle Saint Hélier is the lead sponsor of 23 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults:
Minors:
Caregivers:
Exclusion Criteria:
majors : Participants requiring urgent medical care that prevents them from completing an 8-week familiarisation period with the treatment
minors : Individuals requiring urgent care that prevents them from completing an 8-week acclimatisation period
Caregiver: Vulnerable individuals referred to in Articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code are excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For each group, once they have been briefed, the following materials will be provided: * A monitoring kit and a logbook to support the user and monitor their adaptation to the treatment; * An information leaflet entitled 'Adapting to conventional treatment'; * A dummy wristband designed to help the user get used to wearing the 'Embrace Plus' wristband, which measures the level of anxiety.
Behavioral: Traditional care habituation programme · Device: Embrace Plus wristband · Device: Dummy wristband
In addition to the traditional care habituation materials provided to participants in the control group, participants in this group will also receive: * A PREPASOINS\_VR immersive virtual reality familiarisation kit to prepare participants for upcoming medical and care procedures through immersive 360° videos; * An information leaflet explaining how to use the virtual reality familiarisation kit. The virtual reality programme includes eight care scenarios covering dental care, dental mobile unit visits, gynaecological and ophthalmological consultations, follow-up appointments for physical medicine and rehabilitation, somatic assessments, blood tests and electrocardiograms.
Behavioral: Traditional care habituation programme · Device: Embrace Plus wristband · Device: PREPASOINS_VR virtual reality headset · Device: Dummy wristband
A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS\_VR).
The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention.
An immersive virtual reality headset used with the PREPASOINS\_VR solution. The device enables participants to view immersive 360-degree videos presenting different medical and care scenarios as part of the care familiarisation programme. It is used exclusively in the experimental group.
A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters.
Skin Conductance (SC) During the Actual Treatment Procedure (µS)
Skin conductance (SC), expressed in microsiemens (µS), measured using an Empatica wristband during the actual treatment procedure at Visit 1. Skin conductance reflects changes in the electrical conductance of the skin associated with sweat secretion by the eccrine sweat glands, particularly those located on the palms and soles. Skin conductance is a physiological measure of electrodermal activity (EDA) associated with sympathetic nervous system activity.
Time frame: At Visit 1, during the actual treatment procedure (2-3 months after enrolment).
Change From Baseline in Caregiver-Reported Patient Anxiety Score on the Visual Analogue Scale at 2-3 Months
Patient anxiety score as perceived and reported by the caregiver, measured using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates maximum anxiety. The assessment is performed at inclusion (baseline) and at Visit 1 (2-3 months after enrolment). The change in anxiety score between baseline and Visit 1 will be reported. Higher scores indicate higher levels of perceived anxiety (worse outcome).
Time frame: At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
Percentage of Care Provided During the Actual Treatment Procedure (%)
The degree of care provision during the actual treatment procedure, assessed by the healthcare professional using a numerical scale ranging from 0% (care not provided) to 100% (care fully provided). Intermediate values indicate partial care provision. A derived categorical variable will also be reported, distinguishing complete care provision (100%) from incomplete care provision (partial care provision or no care provided).
Time frame: Visit 1, during the actual treatment procedure (2-3 months after enrolment).
Use of Premedication Before the Treatment Procedure (Yes/No)
Use of premedication before the actual treatment procedure, recorded as a binary variable (yes/no). When premedication is used, its type (pharmacological or non-pharmacological) will also be recorded. For pharmacological premedication, the medication name and dose will be documented, when applicable.
Time frame: At Visit 1 (between 2 and 3 months after enrolment).
Use and Acceptance of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA)
Use of conscious sedation with nitrous oxide/oxygen (MEOPA) during the actual treatment procedure, recorded as a categorical variable: administered and accepted, refused, or not used.
Time frame: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Duration of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA) (Minutes)
Duration of MEOPA administration during the actual treatment procedure, measured in minutes among participants who receive conscious sedation.
Time frame: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Number of Preparatory Visits Before the Actual Treatment Procedure
Number of preparatory visits ("dry runs") completed before the actual treatment procedure. A preparatory visit is defined as a visit during which the patient attends the treatment setting but the planned treatment is not performed. The total number of preparatory visits completed before the actual treatment will be recorded.
Time frame: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Pain Score During the Treatment Procedure Measured Using the Postoperative Pain Assessment Grid for Individuals with Intellectual Disabilities (GED-DI)
Pain experienced by the patient during the treatment procedure, measured using the Postoperative Version of the Pain Assessment Grid for Individuals with Intellectual Disabilities (Grille d'Évaluation de la Douleur - Déficience Intellectuelle, GED-DI). The scale consists of 27 behavioral items, each scored from 0 to 3, resulting in a total score ranging from 0 to 81. The scale is completed after the treatment by the healthcare professional who performed the procedure, with the assistance of a companion when necessary. Higher scores indicate greater pain intensity (worse outcome). Scores of 6-10 indicate mild pain, while scores of 11 or higher indicate moderate to severe pain.
Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
Caregiver Satisfaction With the Care Provided During the Treatment Procedure
Caregiver satisfaction with the care provided during the actual treatment procedure, assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater satisfaction and a better outcome. The questionnaire is completed by the caregiver, if present during the consultation.
Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Healthcare Professional-Rated Ease of Performing the Treatment Procedure
The perceived ease of performing the actual treatment procedure, assessed by the healthcare professional using a 5-point Likert scale ranging from 1 (very difficult) to 5 (very easy). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater ease of performing the procedure and a better outcome.
Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Duration of the Treatment Habituation Period (Days)
Duration of the treatment habituation period, measured in days from the date of the first habituation session to the date of the actual treatment procedure. The duration is calculated as the number of calendar days between these two dates.
Time frame: From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Number of Treatment Habituation Sessions
Total number of habituation sessions completed by each participant between enrolment and the actual treatment procedure.
Time frame: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Recruitment Rate (%)
Proportion of eligible participants who agreed to participate and were enrolled in the study, calculated as the number of enrolled participants divided by the number of eligible participants approached, multiplied by 100.
Time frame: From the start of recruitment until the end of the recruitment period, up to 12 months
Recruitment Speed (Participants per Month)
Average number of participants enrolled per month during the recruitment period, calculated as the total number of enrolled participants divided by the number of months of active recruitment.
Time frame: Up to 12 months
Eligibility Rate (%)
Proportion of individuals assessed for eligibility who met all study eligibility criteria, calculated as the number of eligible individuals divided by the total number of individuals assessed for eligibility, multiplied by 100.
Time frame: Up to 12 months
participant Refusal Rate (%)
Proportion of individuals approached for study participation who declined to participate, calculated as the number of individuals who refused participation divided by the total number of individuals approached, multiplied by 100.
Time frame: Up to 12 months
Intervention Adherence Rate (%)
Proportion of enrolled participants who completed at least two treatment habituation sessions, calculated as the number of participants completing at least two sessions divided by the total number of enrolled participants, multiplied by 100.
Time frame: From enrolment up to Visit 1, up to 3 months
Acceptance Rate of the Dummy Wristband (%)
Proportion of participants who accepted wearing the dummy wristband, calculated as the number of participants who accepted wearing the dummy wristband divided by the total number of participants offered the dummy wristband, multiplied by 100.
Time frame: During the habituation period prior to Visit 1, up to 3 months post-enrolment
Acceptance Rate of the Embrace Plus Wristband on the Treatment Day (%)
Proportion of participants who accepted wearing the Embrace Plus wristband during the actual treatment procedure, calculated as the number of participants who accepted wearing the wristband divided by the total number of participants offered the wristband, multiplied by 100.
Time frame: At Visit 1, up to 3 months post-enrolment
Main Reasons for Non-Participation
Main reasons reported by individuals who declined participation in the study, recorded as categorical data.
Time frame: Up to 12 months
Time Interval Between Initial Contact and Study Inclusion (Days)
Time interval, measured in calendar days, between the date of initial contact with the potential participant and the date of study inclusion.
Time frame: From initial contact until study inclusion, up to 12 months
Participant Follow-up Completion Rate (%)
Proportion of enrolled participants who completed the planned study follow-up assessment at Visit 1, calculated as the number of participants completing Visit 1 divided by the total number of enrolled participants, multiplied by 100
Time frame: From enrolment until Visit 1 (2-3 months after enrolment).
Start is estimated for Dec 2026; primary completion for Mar 2028, 15 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pôle Saint Hélier